Source comparison
Dosage Comparison: Research Protocols Across Study Types
Different research endpoints require different dosing strategies. The following comparison outlines standard Tesamorelin + Ipamorelin dosing used in published research across three common study focuses. | Study Focus | Tesamorelin Dose | Ipamorelin Dose | Tota
This comparison does not assign a generated winner or score.
- Different research endpoints require different dosing strategies. The following comparison outlines standard Tesamorelin + Ipamorelin dosing used in published research across three common study focuses.
- | Study Focus | Tesamorelin Dose | Ipamorelin Dose | Total Daily Dose | Administration Frequency | Typical Duration | Bottom Line ||—|—|—|—|—|—|| Visceral adipose tissue (VAT) reduction | 400–500mcg | 200–300mcg | 600–800mcg | Once daily (PM) | 12–26 weeks | Higher-dose protocols mimic clinical VAT reduction trials; GH secretion peaks align with nocturnal fat oxidation windows || Lean mass preservation during caloric deficit | 200–300mcg | 200–250mcg | 400–550mcg | Once daily (PM) | 8–16 weeks | Moderate dosing maintains anabolic signaling without excessive IGF-1 elevation; pairs with resistance training protocols || GH secretion kinetics and metabolic markers | 100–250mcg | 100–200mcg | 200–450mcg | Once or twice daily | 4–12 weeks | Lower doses allow detailed GH pulse tracking and minimize confounding variables in metabolic endpoint measurement |
- The "once daily PM" administration schedule reflects circadian GH secretion patterns. Endogenous GH pulses occur primarily during slow-wave sleep, and administering GHS peptides 30–60 minutes before sleep augments these natural pulses rather than creating isolated daytime spikes. Some research protocols split the daily dose into morning and evening administrations (e.g., 250mcg AM + 250mcg PM) to maintain more consistent 24-hour GH elevation, particularly in studies measuring continuous metabolic rate or substrate oxidation. There is no definitive evidence that split dosing produces superior outcomes compared to single PM dosing for body composition endpoints, but it may reduce peak GH levels that occasionally trigger transient insulin resistance in susceptible research models.
- Titration schedules matter when initiating new research protocols. Starting at full therapeutic dose without gradual escalation increases the incidence of transient side effects in research subjects, including localized injection site reactions, transient water retention, and mild insulin resistance markers. A standard titration protocol: Week 1–2 at 50% target dose, Week 3–4 at 75% target dose, Week 5+ at 100% target dose. For example, if your target protocol is 500mcg Tesamorelin + 300mcg Ipamorelin (800mcg total), begin at 250mcg + 150mcg for two weeks, increase to 375mcg + 225mcg for two weeks, then advance to full dose. This allows physiological adaptation to elevated GH levels and minimizes disruption to glucose homeostasis and fluid balance.